GDNF Parkinson's race: Amgen plans Phase I with Medtronic device; Genentech licenses neurturin.
Executive Summary
AMGEN GDNF PHASE I TRIALS WILL EXAMINE INTRAVENTRICULAR DOSING as well as standard analysis of safety and tolerability of glial-derived neurotrophic factor. The early-stage Parkinson's disease drug is nearing the start of human trials, and Phase I studies in patients with modest to moderately severe Parkinson's are projected to begin later this year, the company told the financial community at a March 25 meeting in New York City.